GB8513754D0
(en)
*
|
1985-05-31 |
1985-07-03 |
Jones T R |
Anti-cancer quinazoline derivatives
|
GB8625019D0
(en)
*
|
1986-10-18 |
1986-11-19 |
Wellcome Found |
Compounds
|
GB8707053D0
(en)
*
|
1987-03-25 |
1987-04-29 |
Ici Plc |
Anti-tumour agents
|
US4857530A
(en)
*
|
1987-11-03 |
1989-08-15 |
Warner-Lambert Company |
Substituted quinazolinones as anticancer agents
|
GB8727737D0
(en)
*
|
1987-11-26 |
1987-12-31 |
Ici Plc |
Antitumour agents
|
US5019577A
(en)
*
|
1988-04-15 |
1991-05-28 |
Burroughs Welcome Co. |
Novel compounds and use
|
US4940713A
(en)
*
|
1988-04-15 |
1990-07-10 |
Burroughs Wellcome Co. |
Substituted glutamic acids
|
GB8809978D0
(en)
*
|
1988-04-27 |
1988-06-02 |
Ici Plc |
Anti-tumour agents
|
EP0365763A1
(en)
*
|
1988-09-30 |
1990-05-02 |
Agouron Pharmaceuticals, Inc. |
Antiproliferative cyclic compounds
|
GB8829296D0
(en)
*
|
1988-12-15 |
1989-01-25 |
Ici Plc |
Anti-tumour compounds
|
US5252573A
(en)
*
|
1988-12-15 |
1993-10-12 |
Imperial Chemical Industries Plc |
Anti-tumor agents
|
US5286726A
(en)
*
|
1990-04-12 |
1994-02-15 |
The Regents Of The University Of Michigan |
Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
|
IL98167A0
(en)
*
|
1990-05-30 |
1992-06-21 |
Ici Plc |
Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
|
GB9013615D0
(en)
|
1990-06-19 |
1990-08-08 |
Wellcome Found |
Pharmaceutical compounds
|
US5290780A
(en)
*
|
1991-01-30 |
1994-03-01 |
American Cyanamid Co. |
Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
|
GB9105771D0
(en)
*
|
1991-03-19 |
1991-05-01 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5403843A
(en)
*
|
1991-08-12 |
1995-04-04 |
Takeda Chemical Industries, Ltd. |
Pyrrolopyrimidinyalglutaminate derivatives and their use
|
US5145854A
(en)
*
|
1991-11-27 |
1992-09-08 |
Nair Madhavan G |
1-formyl-5,8,10-trideazafolates
|
GB9205320D0
(en)
*
|
1992-03-11 |
1992-04-22 |
Ici Plc |
Anti-tumour compounds
|
GB9205907D0
(en)
*
|
1992-03-18 |
1992-04-29 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
ES2049659B1
(es)
*
|
1992-10-08 |
1994-10-16 |
Ici Plc |
Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
|
GB9223352D0
(en)
*
|
1992-11-06 |
1992-12-23 |
Ici Plc |
Tricyclic compounds
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US7910624B1
(en)
|
1995-03-03 |
2011-03-22 |
The Trustees Of Boston University |
Compositions for the treatment of blood disorders
|
EP0731712A4
(en)
*
|
1993-10-29 |
2005-11-09 |
Univ Boston |
PHYSIOLOGICAL STABILIZED BUTTERIC ACID PREPARATIONS, AND BUTTERIC ACIDS AND DERIVATIVES AS ANTINEOPLASTIC ACTIVE SUBSTANCE
|
US6011000A
(en)
*
|
1995-03-03 |
2000-01-04 |
Perrine; Susan P. |
Compositions for the treatment of blood disorders
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US5593999A
(en)
*
|
1995-06-07 |
1997-01-14 |
Nair; Madhavan G. |
Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
|
US6420427B1
(en)
*
|
1997-10-09 |
2002-07-16 |
Ono Pharmaceutical Co., Ltd. |
Aminobutyric acid derivatives
|
US5912251A
(en)
*
|
1998-01-17 |
1999-06-15 |
Nair; Madhavan G. |
Metabolically inert anti-inflammatory and anti-tumor antifolates
|
CA2324426A1
(en)
*
|
1998-02-11 |
1999-08-19 |
Douglas V. Faller |
Compositions and methods for the treatment of cystic fibrosis
|
GB9904275D0
(en)
|
1999-02-24 |
1999-04-21 |
Cancer Res Campaign Tech |
Anti-cancer compounds
|
US7671200B2
(en)
*
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US6545004B1
(en)
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US6143776A
(en)
*
|
2000-02-02 |
2000-11-07 |
Sunesis Pharmaceuticals, Inc. |
Tosylproline analogs as thymidylate synthase inhibitors
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
EP2332962A1
(en)
|
2001-08-31 |
2011-06-15 |
BTG International Limited |
Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions
|
ATE526028T1
(de)
|
2001-08-31 |
2011-10-15 |
Btg Int Ltd |
Verwendung von cyclopentaägüchinazoline-derivaten zur krebsbehandlung
|
AU2002346471A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
WO2003070701A2
(en)
*
|
2002-02-15 |
2003-08-28 |
Cytokinetics, Inc. |
Syntheses of quinazolinones
|
EP2275102B1
(en)
|
2002-03-13 |
2015-07-29 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
WO2003097053A1
(en)
|
2002-05-09 |
2003-11-27 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
CN100491358C
(zh)
*
|
2002-05-09 |
2009-05-27 |
赛特凯恩蒂克公司 |
嘧啶酮类化合物、组合物及方法
|
US7038048B2
(en)
*
|
2002-05-23 |
2006-05-02 |
Cytokinetics, Inc. |
3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
|
WO2003106426A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
JP2006501201A
(ja)
*
|
2002-07-23 |
2006-01-12 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物および方法
|
US20040048853A1
(en)
*
|
2002-08-21 |
2004-03-11 |
Gustave Bergnes |
Compounds, compositions, and methods
|
PA8580301A1
(es)
|
2002-08-28 |
2005-05-24 |
Pfizer Prod Inc |
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
|
WO2004034972A2
(en)
*
|
2002-09-30 |
2004-04-29 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2003285614B2
(en)
|
2002-12-20 |
2009-05-14 |
Pfizer Products, Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
EP1682534A2
(en)
*
|
2003-11-03 |
2006-07-26 |
Cytokinetics, Inc. |
Pyrimidin-4-one compounds, compositions, and methods
|
WO2005046588A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2004293018B2
(en)
|
2003-11-19 |
2010-02-18 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
WO2005061460A1
(en)
*
|
2003-12-08 |
2005-07-07 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
JP4842929B2
(ja)
|
2004-05-27 |
2011-12-21 |
ファイザー・プロダクツ・インク |
癌治療に有用なピロロピリミジン誘導体
|
AU2005282241B2
(en)
|
2004-09-08 |
2011-03-03 |
Chelsea Therapeutics, Inc. |
Quinazoline derivatives as metabolically inert antifolate compounds.
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
EP2444419A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
PT2361905E
(pt)
|
2005-05-18 |
2013-03-18 |
Array Biopharma Inc |
Inibidores heterocíclicos de mek e seus métodos de utilização
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
PE20080035A1
(es)
|
2005-09-07 |
2008-01-30 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
EP2012786B1
(en)
|
2006-04-18 |
2010-10-06 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
EP2125818A1
(en)
|
2007-01-19 |
2009-12-02 |
Chelsea Therapeutics, Inc. |
New classical antifolates
|
WO2010105112A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Hemaquest Pharmaceuticals, Inc. |
Detection of short-chain fatty acids in biological samples
|
CA2756566A1
(en)
|
2009-03-27 |
2010-09-30 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides as mek inhibitors
|
HRP20171415T4
(hr)
|
2009-06-25 |
2023-03-03 |
Alkermes Pharma Ireland Limited |
Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
WO2011038224A1
(en)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Methods for treating viral disorders
|
CA2779642A1
(en)
|
2009-11-06 |
2011-05-12 |
Chelsea Therapeutics, Inc. |
Enzyme inhibiting compounds
|
WO2011068403A2
(en)
|
2009-12-02 |
2011-06-09 |
Ultimorphix Technologies B.V. |
Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
|
WO2011072086A1
(en)
|
2009-12-08 |
2011-06-16 |
Hemaquest Pharmaceuticals, Inc. |
Methods and low dose regimens for treating red blood cell disorders
|
EP2521711B1
(en)
*
|
2010-01-07 |
2017-08-16 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
HUE030969T2
(en)
|
2010-02-12 |
2017-06-28 |
Pfizer |
Salts and Polymorphs of 8-Fluoro-2- {4 - [(methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-CD] indol-6-one
|
US20110245154A1
(en)
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
WO2011163594A2
(en)
|
2010-06-24 |
2011-12-29 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
EP2611300B1
(de)
|
2010-09-03 |
2016-04-06 |
Bayer Intellectual Property GmbH |
Substituierte anellierte dihydropyrimidinonderivate
|
EP2630134B9
(en)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivatives as smoothened receptor modulators
|
US8658652B2
(en)
|
2010-12-07 |
2014-02-25 |
Chelsea Therapeutics, Inc. |
Antifolate combinations
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
CN103561746B
(zh)
|
2011-03-18 |
2018-05-29 |
奥克梅斯制药爱尔兰有限公司 |
包含脱水山梨糖醇酯的药物组合物
|
AU2012311184A1
(en)
|
2011-09-22 |
2014-03-06 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
CN102424679B
(zh)
*
|
2011-11-15 |
2014-07-30 |
扬子江药业集团有限公司 |
一种雷替曲塞的制备方法
|
EP2827868B8
(en)
|
2012-03-19 |
2019-12-18 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising fatty acid esters
|
CA2867123C
(en)
|
2012-03-19 |
2021-02-16 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
|
CA2867137C
(en)
|
2012-03-19 |
2020-12-08 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
|
CA2885196C
(en)
|
2012-09-19 |
2021-06-22 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions having improved storage stability
|
KR20160058960A
(ko)
|
2013-10-04 |
2016-05-25 |
압토스 바이오사이언시스 인코포레이티드 |
암을 치료하기 위한 조성물과 방법
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN110368360A
(zh)
|
2014-03-20 |
2019-10-25 |
奥克梅斯制药爱尔兰有限公司 |
具有增加的注射速度的阿立哌唑制剂
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
NZ725496A
(en)
|
2014-04-30 |
2019-11-29 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6379296B2
(ja)
*
|
2014-12-02 |
2018-08-22 |
イーライ リリー アンド カンパニー |
1−オキソ−1,2−ジヒドロイソキノリン−7−イル−(5−置換−チオフェン−2−イル)−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるaicarft阻害剤としてのそれらの使用
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
CN104447724B
(zh)
*
|
2014-12-31 |
2017-11-10 |
四川峨嵋山药业有限公司 |
一种雷替曲塞的精制方法
|
JP2018519327A
(ja)
|
2015-06-29 |
2018-07-19 |
ベラステム・インコーポレーテッドVerastem,Inc. |
治療用組成物、組合せ物および使用の方法
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
US20190008869A1
(en)
|
2016-01-13 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
|
CN106957311B
(zh)
*
|
2016-12-29 |
2020-03-31 |
南京正大天晴制药有限公司 |
雷替曲塞的溶剂化物及其制备方法
|
CN106957312B
(zh)
*
|
2016-12-29 |
2019-11-01 |
南京正大天晴制药有限公司 |
雷替曲塞水合物晶型及其制备方法
|
CN112423754A
(zh)
|
2018-03-05 |
2021-02-26 |
奥克梅斯制药爱尔兰有限公司 |
阿立哌唑的给药策略
|
CN109734698B
(zh)
*
|
2019-01-25 |
2020-07-17 |
宏冠生物药业有限公司 |
一种雷替曲塞关键中间体的合成工艺
|
SG11202113215UA
(en)
|
2019-05-31 |
2021-12-30 |
Viracta Subsidiary Inc |
Methods of treating virally associated cancers with histone deacetylase inhibitors
|
MX2021016085A
(es)
|
2019-06-18 |
2022-04-20 |
Pfizer |
Derivados de benzisoxazol sulfonamida.
|
AU2020295006B2
(en)
|
2019-06-19 |
2023-11-09 |
Ctxt Pty Ltd |
Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
|